autoimmune diseases

News

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.

News

Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.

News

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

News

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class to its R&D capabilities.

News

Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.